Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” ” . . In addition, Gb Sciences has 12 U.S. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. THC is a agonist of BC receptors and chronic use of Cannabis may lead to tolerance of these receptors.

Events 48

Events THC Chronic Pain Sleep 48

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

OCTOBER 17, 2019

Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market. The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

AUGUST 24, 2021

. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D., President, Director and Chief Medical Officer. Investor Contact: Robert Schatz.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Veriheal

MAY 3, 2022

The team sought to answer the following: “What are the risks and benefits of obtaining a medical marijuana card for adults who seek medical marijuana for pain, insomnia and anxiety or depressive symptoms?”—a Clinical Trial Sample Size. a necessary question to address as medical marijuana becomes more accessible.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

DECEMBER 1, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

OCTOBER 19, 2021

MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

SpeedWeed

AUGUST 4, 2021

After watching my brother self-medicate for his chronic pain for decades, I didn’t understand how cannabis was important to him as a medicine. I always thought he used his chronic pain as an “excuse” to self-administer what I thought was a toxic drug. . in 2014, I watched my brother walk into a cannabis clinic.

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. “For The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 23, 2021

It’s also important to note that MYMD-1 shows promise in pre-clinical studies as a treatment for immune diseases including rheumatoid arthritis, multiple sclerosis, and Hashimoto’s thyroiditis, and as an anti-fibrotic and anti-proliferation therapeutic.”. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

“This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. Dr. Chapman Bio. Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Based on my clinical experience, it is rare for people to experience CBD-drug interactions at doses below 100mg daily. . Journal of clinical psychopharmacology 41.5

CBD 98

CBD THC Conditions Medicine 98

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. “The 1mg dose showed a significant pain decrease compared to the placebo. .

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

The Cannigma

DECEMBER 12, 2022

Scientists are hopeful that psychedelics might have more of a curative effect when it comes to mental health than many existing treatment options; meaning that unlike most psychiatric medications, psychedelics may be able to prompt long-term changes to our mental state with only a few doses. Are psychedelics safe?

History 119

History Microdosing Research and Development Clinical Trials 119

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Based on my clinical experience, it is rare for people to experience CBD-drug interactions at doses below 100mg daily. [2]. Journal of clinical psychopharmacology 41.5

CBD 52

CBD THC Conditions Medicine 52

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. Christopher M. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. Sinclair is expected to begin the preclinical animal studies at the beginning of 2022 as part of the enabling trials for an IND application with the FDA.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 28, 2021

Virpax recently reported successful results of a Charles River Laboratories single dose toxicology and pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (‘IND’) enabling trials. Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 20, 2021

Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment. Nanomerics has initiated preclinical studies of VRP324. Christopher M.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Green Relief

MAY 13, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. An estimated 4 million to 6 million Americans are on disability because of TBI.

THC 64

THC CBD Cannabinoids Research and Development 64

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. They don’t want to disallow access to the only thing that may stop epileptic seizures in children or is part of a patient’s treatment plan.”

Law 40

Law Seed-To-Sale Hemp Recreational 40